Keisuke Otani, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiosurgery | 7 | 2024 | 1339 | 0.650 |
Why?
|
Cholangitis | 3 | 2015 | 111 | 0.600 |
Why?
|
Deoxycytidine | 3 | 2016 | 878 | 0.560 |
Why?
|
Choledocholithiasis | 2 | 2015 | 50 | 0.560 |
Why?
|
Brachytherapy | 6 | 2020 | 1223 | 0.550 |
Why?
|
Radiation-Sensitizing Agents | 4 | 2020 | 349 | 0.520 |
Why?
|
Prostatic Neoplasms | 10 | 2024 | 11103 | 0.510 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 5 | 2015 | 508 | 0.510 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2016 | 646 | 0.490 |
Why?
|
Fractures, Compression | 1 | 2016 | 131 | 0.460 |
Why?
|
Radiotherapy, Intensity-Modulated | 5 | 2021 | 801 | 0.460 |
Why?
|
Radiation Pneumonitis | 1 | 2014 | 102 | 0.430 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 7 | 2021 | 1655 | 0.430 |
Why?
|
Melanocytes | 1 | 2016 | 509 | 0.420 |
Why?
|
Hemangioendothelioma, Epithelioid | 1 | 2012 | 54 | 0.400 |
Why?
|
Drainage | 2 | 2015 | 1158 | 0.380 |
Why?
|
Radiation Injuries | 3 | 2019 | 1191 | 0.370 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2024 | 9278 | 0.350 |
Why?
|
Interleukin-2 | 2 | 2017 | 1891 | 0.350 |
Why?
|
Decompression, Surgical | 1 | 2015 | 607 | 0.340 |
Why?
|
Cell Cycle | 3 | 2019 | 2926 | 0.340 |
Why?
|
Spinal Fractures | 1 | 2016 | 704 | 0.320 |
Why?
|
Bile Ducts, Intrahepatic | 2 | 2006 | 297 | 0.290 |
Why?
|
Gallbladder Diseases | 1 | 2007 | 139 | 0.270 |
Why?
|
Adenoma, Bile Duct | 1 | 2006 | 29 | 0.270 |
Why?
|
Radiotherapy Dosage | 7 | 2021 | 2898 | 0.260 |
Why?
|
Adrenal Cortex Hormones | 2 | 2015 | 1878 | 0.260 |
Why?
|
Salvage Therapy | 3 | 2024 | 1264 | 0.250 |
Why?
|
Pneumonia | 1 | 2017 | 2142 | 0.240 |
Why?
|
Anti-Inflammatory Agents | 1 | 2014 | 1812 | 0.230 |
Why?
|
Radiography, Abdominal | 1 | 2007 | 534 | 0.230 |
Why?
|
Epithelial Cells | 1 | 2016 | 3666 | 0.230 |
Why?
|
Oropharyngeal Neoplasms | 2 | 2020 | 491 | 0.230 |
Why?
|
Radium | 1 | 2024 | 72 | 0.220 |
Why?
|
Abdomen | 2 | 2017 | 1128 | 0.210 |
Why?
|
Stents | 1 | 2015 | 3177 | 0.210 |
Why?
|
Gastrointestinal Diseases | 2 | 2023 | 1201 | 0.210 |
Why?
|
Osteosarcoma | 2 | 2017 | 896 | 0.190 |
Why?
|
Intracranial Aneurysm | 3 | 2017 | 1286 | 0.190 |
Why?
|
Models, Anatomic | 2 | 2017 | 684 | 0.190 |
Why?
|
Radiotherapy | 2 | 2019 | 1498 | 0.190 |
Why?
|
Liver Neoplasms | 2 | 2018 | 4308 | 0.190 |
Why?
|
Cysts | 1 | 2006 | 680 | 0.180 |
Why?
|
Pancreatic Neoplasms | 2 | 2016 | 5366 | 0.180 |
Why?
|
Prostate-Specific Antigen | 4 | 2024 | 2465 | 0.180 |
Why?
|
Bile Duct Neoplasms | 1 | 2006 | 607 | 0.170 |
Why?
|
Male Urogenital Diseases | 1 | 2019 | 48 | 0.160 |
Why?
|
Uterine Cervical Neoplasms | 3 | 2020 | 2020 | 0.160 |
Why?
|
Particle Accelerators | 1 | 2019 | 174 | 0.160 |
Why?
|
Human papillomavirus 16 | 1 | 2020 | 267 | 0.160 |
Why?
|
Organs at Risk | 1 | 2021 | 359 | 0.160 |
Why?
|
Prostate | 2 | 2024 | 1772 | 0.150 |
Why?
|
Carcinosarcoma | 1 | 2019 | 106 | 0.150 |
Why?
|
Papillomavirus Infections | 2 | 2020 | 1615 | 0.150 |
Why?
|
Amines | 1 | 2019 | 280 | 0.150 |
Why?
|
Radiation Tolerance | 2 | 2020 | 478 | 0.150 |
Why?
|
Liver Diseases | 1 | 2006 | 1300 | 0.150 |
Why?
|
Melanoma | 1 | 2016 | 5694 | 0.150 |
Why?
|
Japan | 3 | 2018 | 1373 | 0.140 |
Why?
|
Aged, 80 and over | 16 | 2020 | 58946 | 0.140 |
Why?
|
Gastrointestinal Tract | 2 | 2020 | 834 | 0.140 |
Why?
|
Glutamates | 1 | 2018 | 385 | 0.140 |
Why?
|
Neurosurgical Procedures | 3 | 2017 | 2067 | 0.130 |
Why?
|
Radiometry | 2 | 2019 | 812 | 0.130 |
Why?
|
Vaginal Neoplasms | 1 | 2016 | 104 | 0.130 |
Why?
|
Pancreatitis | 3 | 2015 | 1097 | 0.130 |
Why?
|
Prostatectomy | 1 | 2024 | 1825 | 0.130 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2019 | 474 | 0.120 |
Why?
|
Aged | 25 | 2023 | 169266 | 0.120 |
Why?
|
Decision Trees | 1 | 2017 | 505 | 0.120 |
Why?
|
Male | 31 | 2024 | 360675 | 0.120 |
Why?
|
Cell Physiological Phenomena | 1 | 2016 | 149 | 0.120 |
Why?
|
Humans | 45 | 2024 | 761098 | 0.110 |
Why?
|
Benzimidazoles | 1 | 2019 | 858 | 0.110 |
Why?
|
Fractures, Spontaneous | 1 | 2016 | 231 | 0.110 |
Why?
|
Phantoms, Imaging | 2 | 2019 | 2515 | 0.110 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2018 | 677 | 0.110 |
Why?
|
Lung Neoplasms | 3 | 2020 | 13382 | 0.110 |
Why?
|
Middle Aged | 22 | 2020 | 220835 | 0.110 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2020 | 4021 | 0.110 |
Why?
|
Surgical Instruments | 1 | 2016 | 383 | 0.110 |
Why?
|
Hospitals, University | 1 | 2015 | 566 | 0.110 |
Why?
|
Respiration | 1 | 2019 | 1656 | 0.100 |
Why?
|
Androgens | 1 | 2020 | 1283 | 0.100 |
Why?
|
Movement | 1 | 2019 | 1476 | 0.100 |
Why?
|
Retrospective Studies | 11 | 2024 | 80673 | 0.100 |
Why?
|
Injections, Intramuscular | 1 | 2012 | 555 | 0.090 |
Why?
|
Treatment Outcome | 11 | 2023 | 64670 | 0.090 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2023 | 2223 | 0.090 |
Why?
|
Doxorubicin | 1 | 2018 | 2224 | 0.090 |
Why?
|
Breast Neoplasms | 2 | 2019 | 20981 | 0.090 |
Why?
|
Epidemiologic Methods | 1 | 2016 | 1336 | 0.090 |
Why?
|
Cell Line, Tumor | 5 | 2020 | 16947 | 0.090 |
Why?
|
Survival Rate | 6 | 2020 | 12727 | 0.090 |
Why?
|
Preoperative Care | 2 | 2016 | 2242 | 0.080 |
Why?
|
Antioxidants | 1 | 2018 | 1667 | 0.080 |
Why?
|
Sphincterotomy, Endoscopic | 1 | 2009 | 44 | 0.080 |
Why?
|
Adenocarcinoma | 2 | 2018 | 6340 | 0.080 |
Why?
|
Quality Assurance, Health Care | 1 | 2019 | 2165 | 0.080 |
Why?
|
Urogenital System | 2 | 2019 | 88 | 0.080 |
Why?
|
Mastectomy, Segmental | 1 | 2014 | 955 | 0.080 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2014 | 1784 | 0.080 |
Why?
|
Algorithms | 2 | 2019 | 14023 | 0.080 |
Why?
|
Esophageal Neoplasms | 1 | 2019 | 1658 | 0.080 |
Why?
|
Vascular Surgical Procedures | 1 | 2017 | 1489 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 6 | 2020 | 20600 | 0.070 |
Why?
|
Colorectal Neoplasms | 2 | 2020 | 6919 | 0.070 |
Why?
|
Gabexate | 1 | 2007 | 12 | 0.070 |
Why?
|
Torsion Abnormality | 1 | 2007 | 91 | 0.070 |
Why?
|
Stomach Neoplasms | 1 | 2017 | 1458 | 0.070 |
Why?
|
Endometrial Neoplasms | 1 | 2016 | 1365 | 0.070 |
Why?
|
Kidney Diseases | 1 | 2018 | 2092 | 0.070 |
Why?
|
Neurosurgery | 1 | 2013 | 679 | 0.070 |
Why?
|
Acute Disease | 2 | 2015 | 7240 | 0.070 |
Why?
|
Mice, Inbred C3H | 2 | 2017 | 914 | 0.070 |
Why?
|
Female | 20 | 2020 | 392458 | 0.070 |
Why?
|
Cholecystectomy, Laparoscopic | 1 | 2007 | 231 | 0.060 |
Why?
|
Head and Neck Neoplasms | 1 | 2020 | 2896 | 0.060 |
Why?
|
Bone Neoplasms | 1 | 2017 | 2527 | 0.060 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2018 | 2293 | 0.060 |
Why?
|
Ultrasonography, Doppler | 1 | 2007 | 462 | 0.060 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2015 | 1891 | 0.060 |
Why?
|
Radiation Dosage | 3 | 2019 | 1966 | 0.060 |
Why?
|
Education, Medical, Graduate | 1 | 2017 | 2372 | 0.060 |
Why?
|
Postoperative Complications | 3 | 2016 | 15634 | 0.060 |
Why?
|
Glioma | 1 | 2019 | 3452 | 0.060 |
Why?
|
Antibodies, Monoclonal | 2 | 2017 | 9185 | 0.060 |
Why?
|
Palliative Care | 1 | 2019 | 3593 | 0.060 |
Why?
|
Models, Biological | 2 | 2019 | 9455 | 0.060 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 1 | 2023 | 106 | 0.050 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2016 | 880 | 0.050 |
Why?
|
Imaging, Three-Dimensional | 3 | 2019 | 4060 | 0.050 |
Why?
|
Antineoplastic Agents | 2 | 2017 | 13630 | 0.050 |
Why?
|
Feasibility Studies | 3 | 2019 | 5249 | 0.050 |
Why?
|
Recombinant Proteins | 1 | 2012 | 6507 | 0.050 |
Why?
|
Colitis, Ulcerative | 1 | 2015 | 1921 | 0.050 |
Why?
|
Androgen Antagonists | 2 | 2023 | 1408 | 0.050 |
Why?
|
Autoimmune Diseases | 1 | 2015 | 2243 | 0.050 |
Why?
|
Crohn Disease | 1 | 2015 | 2279 | 0.050 |
Why?
|
Tumor Burden | 2 | 2019 | 1892 | 0.050 |
Why?
|
Animals | 7 | 2019 | 168083 | 0.050 |
Why?
|
Immunotherapy | 1 | 2017 | 4642 | 0.050 |
Why?
|
Adult | 10 | 2020 | 221083 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 3 | 2023 | 36418 | 0.050 |
Why?
|
Recurrence | 1 | 2014 | 8456 | 0.050 |
Why?
|
Abdominal Pain | 1 | 2007 | 1071 | 0.050 |
Why?
|
Clinical Competence | 1 | 2017 | 4786 | 0.050 |
Why?
|
Cerebral Angiography | 2 | 2017 | 1281 | 0.050 |
Why?
|
Ouabain | 1 | 2020 | 246 | 0.040 |
Why?
|
Biopsy | 2 | 2015 | 6781 | 0.040 |
Why?
|
Mutation | 1 | 2024 | 30006 | 0.040 |
Why?
|
Glycoproteins | 1 | 2007 | 2203 | 0.040 |
Why?
|
Pancreas | 1 | 2006 | 1685 | 0.040 |
Why?
|
Cystectomy | 1 | 2023 | 634 | 0.040 |
Why?
|
Combined Modality Therapy | 3 | 2017 | 8519 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6482 | 0.040 |
Why?
|
DNA Damage | 2 | 2019 | 2443 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2019 | 9025 | 0.040 |
Why?
|
Gamma Rays | 1 | 2019 | 318 | 0.040 |
Why?
|
Cisplatin | 1 | 2023 | 1651 | 0.040 |
Why?
|
Receptors, Androgen | 1 | 2024 | 1077 | 0.040 |
Why?
|
Lipid Peroxidation | 1 | 2018 | 271 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 2017 | 312 | 0.030 |
Why?
|
Mice | 3 | 2019 | 81324 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2023 | 3591 | 0.030 |
Why?
|
Hepatitis C | 1 | 2006 | 1579 | 0.030 |
Why?
|
Angiography, Digital Subtraction | 1 | 2017 | 335 | 0.030 |
Why?
|
Glutathione | 1 | 2018 | 581 | 0.030 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 890 | 0.030 |
Why?
|
Superoxide Dismutase | 1 | 2018 | 593 | 0.030 |
Why?
|
Lasers | 1 | 2019 | 952 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 10755 | 0.030 |
Why?
|
Treatment Failure | 1 | 2020 | 2643 | 0.030 |
Why?
|
High-Throughput Screening Assays | 1 | 2020 | 931 | 0.030 |
Why?
|
HCT116 Cells | 1 | 2015 | 404 | 0.030 |
Why?
|
DNA, Viral | 1 | 2020 | 2195 | 0.030 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39121 | 0.030 |
Why?
|
Risk Factors | 3 | 2018 | 74219 | 0.030 |
Why?
|
G1 Phase | 1 | 2015 | 403 | 0.030 |
Why?
|
Prognosis | 3 | 2019 | 29672 | 0.030 |
Why?
|
Gastrectomy | 1 | 2017 | 671 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2019 | 1120 | 0.030 |
Why?
|
Ultrasonography | 1 | 2006 | 5971 | 0.030 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2019 | 876 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2007 | 12975 | 0.020 |
Why?
|
Neuronavigation | 1 | 2013 | 166 | 0.020 |
Why?
|
Middle Cerebral Artery | 1 | 2013 | 274 | 0.020 |
Why?
|
Microarray Analysis | 1 | 2015 | 748 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 1089 | 0.020 |
Why?
|
Computer Graphics | 1 | 2013 | 338 | 0.020 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2020 | 1520 | 0.020 |
Why?
|
Spleen | 1 | 2017 | 2290 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12058 | 0.020 |
Why?
|
Apoptosis | 2 | 2019 | 9478 | 0.020 |
Why?
|
Propensity Score | 1 | 2018 | 1913 | 0.020 |
Why?
|
DNA Repair | 1 | 2019 | 2041 | 0.020 |
Why?
|
Lymphocytes | 1 | 2017 | 2603 | 0.020 |
Why?
|
Educational Measurement | 1 | 2017 | 1251 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2017 | 2913 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2020 | 2827 | 0.020 |
Why?
|
Phosphorylation | 1 | 2019 | 8303 | 0.020 |
Why?
|
Regression Analysis | 1 | 2018 | 6343 | 0.020 |
Why?
|
Brain Mapping | 1 | 2023 | 6635 | 0.020 |
Why?
|
Prospective Studies | 3 | 2024 | 54419 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5828 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 4908 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2018 | 8164 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2018 | 3114 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6817 | 0.020 |
Why?
|
Cell Survival | 1 | 2016 | 5776 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2015 | 1589 | 0.020 |
Why?
|
Biological Products | 1 | 2015 | 913 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2020 | 3196 | 0.020 |
Why?
|
Software | 1 | 2019 | 4433 | 0.010 |
Why?
|
Logistic Models | 1 | 2019 | 13254 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2017 | 4574 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2017 | 3092 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2015 | 4538 | 0.010 |
Why?
|
Emergencies | 1 | 2009 | 1217 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2019 | 9001 | 0.010 |
Why?
|
Computer Simulation | 1 | 2016 | 6225 | 0.010 |
Why?
|
Kidney | 1 | 2018 | 7034 | 0.010 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2009 | 1116 | 0.010 |
Why?
|
Young Adult | 2 | 2019 | 59199 | 0.010 |
Why?
|
Databases, Factual | 1 | 2015 | 7969 | 0.010 |
Why?
|
Adolescent | 2 | 2019 | 88271 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2015 | 8529 | 0.010 |
Why?
|
Risk Assessment | 1 | 2020 | 24013 | 0.010 |
Why?
|
Time Factors | 1 | 2020 | 39953 | 0.010 |
Why?
|
Prevalence | 1 | 2015 | 15717 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 11732 | 0.010 |
Why?
|
Incidence | 1 | 2015 | 21357 | 0.010 |
Why?
|
Internship and Residency | 1 | 2017 | 5879 | 0.010 |
Why?
|
Length of Stay | 1 | 2009 | 6420 | 0.010 |
Why?
|
Age Factors | 1 | 2009 | 18385 | 0.010 |
Why?
|
Child | 1 | 2019 | 80134 | 0.010 |
Why?
|
Hospitalization | 1 | 2009 | 10712 | 0.010 |
Why?
|